IP Verse

Methods Of Treating Ocular Conditions - EP3848028

The patent EP3848028 was granted to Oyster Point Pharma on Oct 16, 2024. The application was originally filed on Oct 19, 2015 under application number EP20212556A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3848028

OYSTER POINT PHARMA
Application Number
EP20212556A
Filing Date
Oct 19, 2015
Status
Granted And Under Opposition
Apr 27, 2024
Grant Date
Oct 16, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLEFeb 6, 2025HOFFMANN EITLEADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2008057938
DESCRIPTIONWO2009111550
DESCRIPTIONWO2010028011
DESCRIPTIONWO2010028033
OPPOSITIONEP1214062
OPPOSITIONUS2006084656
OPPOSITIONUS2011274628
OPPOSITIONWO2009069126
OPPOSITIONWO2016064759
SEARCHEP1214062
SEARCHWO2009069126

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- A Gupta, T Heigle, S C Pflugfelder, "Nasolacrimal Stimulation of Aqueous Tear production", Cornea, Masson Pub. USA, (19971101), vol. 16, no. 6, ISSN 0277-3740, pages 645 - 648, XP009560118-
OPPOSITION- European Medicines Agency (ema), "EPAR summary for the public Champix varenicline", EMA/163166/2014 EMEA/H/C/00699, (20140403), pages 1 - 3, EMA/163166/2014 EMEA/H/C/00699, URL: https://www.ema.europa.eu/en/documents/overview/champix-epar-summary-public_en.pdf, (20210927), XP055844659-
OPPOSITION- Ferguson Tanner J., Messer Brooke, Risbrudt Nicholas, Stofferahn Seth, Greenwood Michael, "Varenicline Solution Nasal Spray for the Treatment of Dry Eye Disease Following LASIK", Ophthalmology and Therapy, (20240601), vol. 13, no. 6, doi:10.1007/s40123-024-00949-4, ISSN 2193-8245, pages 1693 - 1701, XP093260644
OPPOSITION- Dartt Darlene A., "Author Manuscript: Neural regulation of lacrimal gland secretory processes: Relevance in dry eye diseases", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, GB , (20090501), vol. 28, no. 3, doi:10.1016/j.preteyeres.2009.04.003, ISSN 1350-9462, pages 1 - 51, XP093260651
OPPOSITION- Liu L, Chang G-Q, Jiao Y.Q, Simon S.A, "Neuronal nicotinic acetylcholine receptors in rat trigeminal ganglia", Brain Research, ELSEVIER, Amsterdam, NL, NL , (19981101), vol. 809, no. 2, doi:10.1016/S0006-8993(98)00862-2, ISSN 0006-8993, pages 238 - 245, XP093260655
OPPOSITION- Alimohammadi H., Silver Wayne L, "Evidence for Nicotinic Acetylcholine Receptors on Nasal Trigeminal Nerve Endings of the Rat", Chemical Senses, Oxford University Press, (20000201), vol. 25, no. 1, doi:10.1093/chemse/25.1.61, ISSN 1464-3553, pages 61 - 66, XP093260653
OPPOSITION- Wirta David, Torkildsen Gail L., Boehmer Blair, Hollander David A., Bendert Edward, Zeng Lijuan, Ackermann Michael, Nau Jeffrey, "ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease", Cornea, Masson Pub. USA, (20221001), vol. 41, no. 10, doi:10.1097/ICO.0000000000002941, ISSN 0277-3740, pages 1207 - 1216, XP093260608

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents